Celgene Corp. (CELG) is expected to report Q4 earnings before the market open on Thursday, January 28, with a conference call scheduled for 9 am ET.
GuidanceThe consensus estimate is 62c for EPS and $743.32M for revenue, according to First Call. On January 11, Celgene pre-announced its Q4 results with an EPS view of 62c. Positive drivers for the company include expanding usage and international growth of Revlimid and the company's healthy pipeline. Possible negative drivers for Celgene include an overestimation of Revlimid sales and the increasingly competitive blood cancer market.
Analyst ViewsOn January 13, Celgene's target was raised to $68 from $60 at RBC Capital, reflecting what the firm sees as new positive data on Revlimid and bullish 2010 revenue guidance, as well as better than expected Q4 results. The firm maintains an Outperform rating on the stock.
No comments:
Post a Comment